Publications COMBAT-MS
Articles generated within the framework of the COMBAT-MS study sorted by year of publication
2024
- Alping P, Neovius M, Piehl F, Frisell T. Real-World Healthcare Cost Savings and Reduced Relapse Rate with Off-Label Rituximab versus Disease-Modifying Treatments Approved for Relapsing-Remitting Multiple Sclerosis: A Nationwide Cost-Effectiveness Study. Ann Neurol. 2024: 95(6):1099-1111. PMID: 38529711.
- Englund S, Frisell T, Qu Y, Gandhi K, Hultén A; Kierkegaard M, Piehl F, Longinetti E. Trajectories of self-reported fatigue following initiation of multiple sclerosis disease modulating therapy. J Neurol Neurosurg Psychiatry. 2024: ;95(11):1012-1020. PMID: 38744460.
- Hu Y, Frisell T, Alping P, Song H, Pawitan Y, Fang F*, Piehl F*. Hospital-treated infections and risk of disability worsening in multiple sclerosis. Ann Neurol. 2024. Online ahead of print. PMID: 38984615.
- Longinetti E, Englund S, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould AM, Lycke J, Nilsson P, Salzer J, Svenningsson A, Mellergård J, Olsson T, Piehl F, Frisell T. Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy. J Neurol Neurosurg Psychiatry. 2024: 95(2):134-141. PMID: 37558400
2023
- Langer-Gould AM, Smith JB, Gonzales EG, Piehl F, Li BH. Multiple Sclerosis, Disease-Modifying Therapies, and Infections. Neurol Neuroimmunol Neuroinflamm. 2023;10(6):e200164. PMID: 37813594
- Fink K, Gorczyca A, Alping P, Englund S, Farmand S, Langer-Gould AM, Piehl F, McKay K, Frisell T, Razaz N. Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study. Mult Scler. 2023;29(6):731-740. PMID: 37073483
- Englund S, Kierkegaard M, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Mellergård J, Olsson T, Longinetti E, Frisell T, Piehl F. Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohort. Mult Scler Relat Disord. 2023: 70:104481. PMID: 36603296
2022
- Starvaggi Cucuzza, C, Longinetti E, Ruffin N, Evertsson B, Kockum I, Jagodic M, Al Nimer F, Frisell T, Piehl F. Sustained low relapse rate with highly variable B cell re-population dynamics with extended rituximab dosing intervals in multiple sclerosis. Neurology Neuroimmunology & Neuroinflammation. 2022; 10(1):e200056. PMID: 36411076
- Longinetti E, Bower H, McKay KA, et al. COVID 19 clinical outcomes and DMT of MS patients and population-based controls. Ann Clin Transl Neurol. 2022;9(9):1449-1458. PMID: 35993445.
- Platten M, Ouellette R, Herranz E, et al. Cortical and white matter lesion topology influences focal corpus callosum atrophy in multiple sclerosis. J Neuroimaging. 2022;1-9. PMID: 35165979.
- Brusini I, Platten M, Ouellette R, Piehl F, Wang C, Granberg T. Automatic deep learning multicontrast corpus callosum segmentation in multiple sclerosis. J Neuroimaging. 2022;32(3):459-470. PMID: 35083815.
2021
- Alping P, Burman J, Lycke J, Frisell T, Piehl F. Safety of alemtuzumab and autologous hematopoietic stem cell transplantation compared to noninduction therapies for multiple sclerosis. Neurology. 2021;96(11):e1574-e1584. PMID: 33514645.
- Longinetti E, Frisell T, Englund S, Reutfors J, Fang F, Piehl F. Risk of depression in multiple sclerosis across disease-modifying therapies. Mult Scler. 2021;15:13524585211031128. PMID: 34264143.
- Spelman T, Magyari M, Piehl F, et al. Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies. JAMA Neurol. 2021;78(10):1197-1204. PMID: 34398221.
- Platten M, Brusini I, Andersson O, et al. Deep learning corpus callosum segmentation as a neurodegenerative marker in multiple sclerosis. J Neuroimaging. 2021;31:493-500. PMID: 33587820.
- Asplund Högelin K, Ruffin N, Pin E, et al. Development of humoral and cellular immunological memory against SARS-CoV-2 despite B-cell depleting treatment in multiple sclerosis. iScience. 2021;4(9):103078. PMID: 34490414.
- Langer-Gould A, Smith JB, Li BH, et al. Multiple sclerosis, rituximab, and COVID 19. Ann Clin Transl Neurol. 2021;8(4):938-943. PMID: 33783140.
- McKay KA, Piehl F, Englund S, et al. Rituximab infusion timing, cumulative dose, and hospitalization for COVID 19: evidence from the nationwide COMBAT-MS Cohort. JAMA Netw Open. 2021;4(12):e2136697. PMID: 34851401.
2020
- Luna G, Alping P, Burman J, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77(2):184-191. PMID: 31589278.
- Alping P, Askling J, Burman J, et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Ann Neurol. 2020;87(5):688-699. PMID: 32056253.
- Smith JB, Hellwig K, Fink K, Lyell DJ, Piehl F, Langer-Gould A. Rituximab, MS, and pregnancy. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e734. PMID: 32358226.
- Razaz N, Piehl F, Frisell T, Langer-Gould AM, McKay KA, Fink K. Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab. Neurol Neuroimmunol Neuroinflamm. 2020;7(6):e903. PMID: 33087582.
- Ouellette R, Treaba CA, Granberg T, et al. 7 T imaging reveals a gradient in spinal cord lesion distribution in multiple sclerosis. Brain. 2020;143(10);2973-2987. PMID: 32935834.
- Ouellette R, Mangeat G, Polyak I, et al. Validation of rapid magnetic resonance myelin imaging in multiple sclerosis. Ann Neurol. 2020;87(5):710-724. PMID: 32057118.
- Platten M, Martola J, Fink K, Ouellette R, Piehl F, Granberg T. MRI-based manual versus automated corpus callosum volumetric measurements in multiple sclerosis. J Neuroimaging. 2020;30:198-204. PMID: 31750599.
2019
- Alping P, Piehl F, Langer-Gould A, Frisell T; COMBAT-MS Study Group. Validation of the Swedish Multiple Sclerosis Register: further improving a resource for pharmacoepidemiologic evaluations. Epidemiology. 2019;30(2):230-233. PMID: 30721167.
2018
- Dunn N, Juto A, Ryner M, et al. Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies. Mult Scler. 2018;24(9):1224-1233. PMID: 28762877.